| General Information | |
|---|---|
| ZINC ID | ZINC000040976165 |
| Molecular Weight (Da) | 474 |
| SMILES | Clc1ccc(-n2c(-c3ccc(Cl)cc3Cl)nc3c(NN4CCCCC4)ncnc32)cc1 |
| Molecular Formula | C22Cl3N6 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 126.563 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| LogP | 6.71 |
| Activity (Ki) in nM | 1.6982 |
| Polar Surface Area (PSA) | 58.87 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.906 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 21 |
| Fraction csp3 | 0.23 |
| Ilogp | 4.25 |
| Xlogp3 | 6.65 |
| Wlogp | 5.68 |
| Mlogp | 4.96 |
| Silicos-it log p | 4.49 |
| Consensus log p | 5.21 |
| Esol log s | -7.2 |
| Esol solubility (mg/ml) | 0.0000296 |
| Esol solubility (mol/l) | 6.25E-08 |
| Esol class | Poorly sol |
| Ali log s | -7.69 |
| Ali solubility (mg/ml) | 0.00000971 |
| Ali solubility (mol/l) | 2.05E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.85 |
| Silicos-it solubility (mg/ml) | 0.00000067 |
| Silicos-it solubility (mol/l) | 1.42E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.47 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.29 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.274 |
| Logd | 4.678 |
| Logp | 5.213 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 97.84% |
| Vdss | 1.114 |
| Fu | 2.89% |
| Cyp1a2-inh | 0.963 |
| Cyp1a2-sub | 0.189 |
| Cyp2c19-inh | 0.919 |
| Cyp2c19-sub | 0.071 |
| Cl | 6.311 |
| T12 | 0.062 |
| H-ht | 0.86 |
| Dili | 0.966 |
| Roa | 0.114 |
| Fdamdd | 0.896 |
| Skinsen | 0.061 |
| Ec | 0.003 |
| Ei | 0.014 |
| Respiratory | 0.713 |
| Bcf | 2.978 |
| Igc50 | 5.173 |
| Lc50 | 7.099 |
| Lc50dm | 6.275 |
| Nr-ar | 0.017 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.958 |
| Nr-aromatase | 0.984 |
| Nr-er | 0.698 |
| Nr-er-lbd | 0.051 |
| Nr-ppar-gamma | 0.424 |
| Sr-are | 0.926 |
| Sr-atad5 | 0.303 |
| Sr-hse | 0.894 |
| Sr-mmp | 0.855 |
| Sr-p53 | 0.909 |
| Vol | 431.535 |
| Dense | 1.094 |
| Flex | 0.103 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.416 |
| Synth | 2.982 |
| Fsp3 | 0.227 |
| Mce-18 | 61.63 |
| Natural product-likeness | -1.088 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |